Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
CLDX
vs
S&P 500
CLDX
S&P 500
Over the past 12 months, CLDX has underperformed S&P 500, delivering a return of +13% compared to S&P 500's +16% growth.
Stocks Performance
CLDX vs S&P 500
Performance Gap
CLDX vs S&P 500
Performance By Year
CLDX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Celldex Therapeutics Inc
Glance View
Celldex Therapeutics is a biotechnology company that develops antibody-based medicines, mainly for diseases driven by the immune system. Its research focuses on conditions such as allergic and inflammatory disorders, and it also has programs in oncology. The company is not a drug store or manufacturer; it is a drug developer that designs candidates, tests them in clinical trials, and tries to turn promising science into approved treatments. Because Celldex is still a development-stage biotech, it does not sell a broad portfolio of marketed drugs. Instead, it makes money mainly through research funding, collaboration deals, and potential milestone or licensing payments tied to its drug programs. If a medicine wins approval, the long-term value would come from selling or partnering that treatment for use by doctors and patients. What makes Celldex different is its focus on immune targets that can calm overactive disease pathways, especially in allergy and inflammation. That puts it in the high-risk, high-reward part of biotech: the company’s value depends on its patents, lab data, and clinical trial results rather than factories, stores, or large recurring product sales.